



Institute  
and Faculty  
of Actuaries

# Too Much, Too Young, Too Early

Carl Padget and Gráinne Hampson

Pacific Life Re



# Too Much, Too Young, Too Early

- **What can we learn about anti-selection by analysing Critical Illness claims data?**
- **Can we use this data to identify anti-selective Critical Illnesses?**
- **How can we improve our underwriting to reduce the potential to anti-select?**



# Too Much, Too Young, Too Early

## Too Young?

❖ **Average age at claim**



# Breast Cancer

## Too Young?

Average age at diagnosis:

❖ POPULATION: 55

❖ CLAIMANTS: 44



Institute  
and Faculty  
of Actuaries

# Bowel Cancer

## Too Young?

Average age at diagnosis:

❖ POPULATION: 64

❖ CLAIMANTS: 47



Institute  
and Faculty  
of Actuaries

# Too Much, Too Young, Too Early

## Too Much, Too Early?

- ❖ Population vs. insured incidence
- ❖ Average claim amount by duration



# Multiple Sclerosis – Proportion of all claims Too Much?

Multiple Sclerosis incidence as a percentage of all critical illnesses:  
Population vs. Insured Claims

Cancer site	Population Incidence*	Insured Claims Incidence	Difference
Multiple Sclerosis (Female)	2.0%	6.3%	+ 210%

\*Incidence and prevalence of multiple sclerosis in the UK 1990–2010: a descriptive study in the General Practice Research Database



Institute  
and Faculty  
of Actuaries

# Multiple Sclerosis - Cover Amount and Duration

## Too Much, Too Early?

Condition \ Policy Duration	Average Claim Amount	Average Claim Amount vs. All Claims	0	1	2	3	4	5+
Death	53,594	94%	108%	104%	105%	87%	84%	75%
Benign Brain Tumour	73,345	129%	131%	136%	146%	125%	163%	93%
Coma	63,288	111%	107%	88%	129%	83%	107%	187%
CABG	54,121	95%	92%	110%	94%	100%	79%	94%
Heart Attack	52,445	92%	99%	100%	88%	86%	104%	81%
HVRoR	69,316	122%	196%	136%	128%	174%	97%	86%
Kidney Failure	55,848	98%	138%	92%	106%	93%	86%	88%
MOT	72,051	126%	132%	103%	125%	14%	58%	143%
MND	74,112	130%	152%	64%	79%	181%	138%	111%
<b>Multiple Sclerosis</b>	<b>65,913</b>	<b>116%</b>	<b>137%</b>	<b>118%</b>	<b>132%</b>	<b>104%</b>	<b>96%</b>	<b>108%</b>
Stroke	55,285	97%	114%	93%	85%	113%	90%	89%
TPD	50,685	89%	95%	132%	72%	85%	95%	84%





# Testicular Cancer – Proportion by Cancer Type

## Too Much?

Cancer incidence as a percentage of all cancers:

Population vs. Insured Claims

Cancer site	Population Incidence	Insured Claims Incidence	Difference
Breast	37.8%	54.6%	+44%
Testicular	0.8%	13.0%	+1525%
Malignant Melanoma (Males)	4.3%	7.8%	+81%
Leukaemia (Males)	2.7%	6.5%	140%
Hodgkin's Disease (Male/Female)	0.5% / 0.3%	5.7% / 2.9%	+ 1040% / 867%
Brain Tumour (Males)	1.8%	3.4%	+89%



# Testicular Cancer - Cover Amount and Duration

## Too Much, Too Early?

Cancer Type \ Policy Duration	Average Claim Amount	Average Claim Amount vs. All Claims	0	1	2	3	4	5+
Colon	58,504	94%	130%	95%	132%	87%	76%	94%
Melanoma of skin	74,875	121%	135%	183%	117%	115%	103%	118%
Prostate	58,917	95%	157%	106%	101%	105%	79%	106%
Site not specified	75,457	122%	136%	133%	130%	125%	101%	151%
Testis	75,724	122%	148%	142%	125%	158%	97%	113%
Trachea, bronchus and lung	41,495	67%	110%	80%	44%	81%	53%	68%
Other	61,725	100%	127%	136%	108%	106%	90%	89%
Unknown	54,981	89%	120%	104%	102%	96%	81%	81%



# Testicular Cancer - Average Claim Amount

## Too Much, Too Early?

Average claim: £57,000



Average testicular cancer claim: £75,000



Average testicular cancer claim PY1: £84,000



# Testicular Cancer – What we know

## Too Much, Too Early?

Claims data points to evidence of higher than average anti-selection:

- ❑ Incidence rate 15 times that of population
- ❑ Average claim amount 122% of average Cancer claim
- ❑ Highest claim amounts for early duration claims

Potential for anti-selection:

- ❑ What are the potential risk factors?
- ❑ Can these risk factors be mitigated better?



# Testicular Cancer – Risk Factors

## Too Much, Too Early?

### Cryptoorchidism:

- **6.3x** increased risk in unilateral cases
- **1.7x** increased risk in the other (descended) testicle
- **1/44** lifetime risk in bilateral cases

### Infertility:

- **59%** higher risk in sub-fertile men compared to those with normal fertility levels

### Family History:

- **8-10x** increased risk if brother affected
- **75%** increased risk if an identical twin



# Too Much, Too Young, Too Early?

## What the data tells us

### ➤ Evidence of Anti-Selection:

- Younger age at diagnosis
- Above average claim amounts
- Higher claim amounts in earlier years
- Disproportionate proportion of claims compared to population

### ➤ Conditions of particular concern:


- Testicular cancer
- Breast cancer
- Colon cancer
- Multiple Sclerosis

# How can we improve claims experience?



# Too young..... incidence of breast cancer 2009-2011

Average number of new cases per year and age-specific incidence rates per 100,000 population, females, UK



Approximately 4% of cases with significantly premature presentation of breast cancer  
Atypical and suspicious of a dominant genetic issue



Institute  
and Faculty  
of Actuaries

# Too young... family history current breast cancer screening

Age	Standard Risk	Moderate Risk
	No family history 1 first degree relative >40	1 first degree relative <40 2 first/second degree relatives with an average age of 50+ 3 first/second degree relatives with an average age of >60
	National Screening Programme	Secondary Care
		Lifetime risk at least 17% but less than 30%
20-29	<b>No Screening</b>	<b>No Screening</b>
30-39	<b>No Screening</b>	<b>No Screening</b>
40-49	<b>No Screening*</b>	<b>Annual Mammogram</b>
50+	<b>3 Yearly Routine Mammogram</b>	<b>Annual Mammogram</b>

\*Certain health authorities now invite females aged 47 years for 3 yearly routine breast screening



Institute  
and Faculty  
of Actuaries



# Too young..... current breast cancer screening

Age	High Risk		
	Family history over and above that of “moderate” risk, which include: <ul style="list-style-type: none"> <li>○ 1 first/second degree relative diagnosed with ovarian cancer at any age and 1 first/second degree relative diagnosed with breast cancer before 50.</li> <li>○ 2 first/second degree relatives diagnosed with ovarian cancer at any age</li> </ul>		
	Lifetime risk at least 30%	>30% BRCA carrier but no test	>30% TP53* carrier but no test
	Specialist genetic clinic		
20-29	No Screening	No Screening	Annual MRI
30-39	Consider Annual Mammogram	Annual MRI Consider Annual Mammogram	Annual MRI
40-49	Annual Mammogram	Annual MRI and Mammogram	Annual MRI

\*TP53 = A gene that carries instructions to make tumour protein p53 (TP53). The protein acts as a tumour suppressor by regulating cell division through stopping cells from growing/dividing too fast or in an uncontrolled way.



Institute  
and Faculty  
of Actuaries

# Family history – case study

Life, Critical Illness and TPD £150,000

Female aged 45 years

Application disclosure:-

- Routine mammogram – normal
- Family history ovarian cancer – diagnosed 39 years

Decision?


PLRE comment:-

- Mammogram performed before the routine screening age
- Reason for mammogram is not known
- Family history of 1<sup>st</sup> degree relative with ovarian cancer at any age
- Second degree family history not known



# Too young. incidence of colon cancer 2009-2011

Average number of new cases per year and age-specific incidence rates per 100,000 population, UK



Approximately 5% of cases with significantly premature presentation of colon cancer  
Atypical and suspicious of a dominant genetic issue



Institute and Faculty of Actuaries

# Too young... family history current colon cancer screening

Moderate Family History Risk	Screening	Age at initial screening	Screening interval period
3 first degree relatives none <50	Colonoscopy	50 years	5 yearly to age 75
2 first degree relatives mean age <60	Colonoscopy	50 years	5 yearly to age 75
2 first degree relatives $\geq 60$	Colonoscopy	55 years	Once at age 55 no follow up if result normal
1 first degree relative <50	Colonoscopy	55 years	Once at age 55 no follow up if result normal

Routine UK screening is not before the age of 50 years

A colonoscopy is not typically performed for routine UK screening unless the FOB result is abnormal or unclear



Institute  
and Faculty  
of Actuaries

# Too young... family history current colon cancer screening

High Risk Family History	Screening	Age at initial screening	Screening interval period
<b>HNPCC</b>	Colonoscopy OGD	Colonoscopy from age 25 OGD from age 50	Colonoscopy 18 -24 months OGD 2 yearly
<b>FAP</b>	Colonoscopy or alternating colonoscopy & flexible sigmoidoscopy	Teens	Annual colonoscopy or alternating colonoscopy & flexible sigmoidoscopy until age 30
<b>Peutz-Jeghers Syndrome</b>	Colonoscopy OGD	From age 25	Every 2 years
<b>Juvenile polyposis</b>	Colonoscopy OGD	Colonoscopy from age 15 OGD from age 25	2 yearly colonoscopy and OGD >35 years greater intervals



# Too young..... story so far

## Atypical Screenings:

- Colon cancer screening before the age of 50 years – **atypical!**
- Screening by colonoscopy – **atypical!**
- Breast cancer screening before the age of 50\* years – **atypical!**
- Annual mammogram screening – **atypical!**
- Breast MRI screening – **atypical!**

## Atypical investigations:

Investigations or procedures performed indicate medical professionals are concerned regarding possible causes of symptoms – **so should we!**

In particular, further atypical investigations for consideration:

- Mole Mapping
- MRI Brain
- CTA/MRA
- Lumbar Puncture



# Too much Too young...Atypical investigations – mole mapping

- Mole mapping is performed when there is an increased risk of melanoma – **this is not routine!**
- If clinicians are suspicious or concerned – **so should we!**
- There is usually a history of:-
  - Previous excision of moles with existing ones present
  - Multiple moles 50-100+
  - Family history of melanoma
  - Sun damaged skin
- What does the applicant know that we don't?



**Mole mapping app now available on your phone!**

<https://play.google.com/store/apps/details?id=com.revsoft.doctormole&hl=en>



# Too much Too young... atypical investigations – neurological

- MRI/CT scans of the brain are performed for a reason
- They are looking for a cause of symptoms
- They are costly to perform (UK average circa £500)
- It is not a pleasant experience for the patient ☹️

## What do these terms really mean?

- **Essentially** normal
- No **significant** abnormality
- Nil of **significance**
- Reassured
- Lumbar puncture or CTA/MRA are usually second line as a follow up to imaging
- They are invasive and unpleasant procedures
- There is a risk of complication to the patient ☹️

**Therefore, medical professionals will not request these investigations unless they are concerned or suspicious – SO SHOULD WE!**

**Referral letters should provide a better insight**





# Too much Too young... vague neurological symptoms

Red Flag	Amber Warning	Green Alert
<b>Optic Neuritis</b> <ul style="list-style-type: none"> <li>Diplopia (double vision)</li> <li>Unilateral temporary blindness</li> <li>Nystagmus: uncontrolled eye movement (horizontal/vertical)</li> <li>Pain in the eye</li> </ul>	<b>Dysaesthesia</b> <ul style="list-style-type: none"> <li>Pins and needles</li> <li>Tingling</li> <li>Numbness</li> <li>Burning sensations</li> <li>Crawling sensations</li> </ul>	<b>Labyrinthitis</b> <b>Dizziness</b> <b>Vertigo</b>
<b>Lhermitte's sign / Phenomenon</b> <ul style="list-style-type: none"> <li>Electric shock sensation passing down the back when moving the neck</li> </ul>	<b>Balance problems</b> <ul style="list-style-type: none"> <li>Lack of co-ordination</li> <li>Clumsiness</li> <li>Gait</li> <li>Fall / Unsteadiness</li> </ul>	<b>Tinnitus</b> <b>Hearing Loss</b>
<b>Trigeminal Neuralgia</b> <ul style="list-style-type: none"> <li>Unilateral or bilateral severe (sharp, stabbing, electric shock sensation) facial pain</li> </ul>	<b>Cognitive difficulties</b> <ul style="list-style-type: none"> <li>Memory / Confusion</li> <li>Concentration</li> <li>Attention</li> <li>Confusion</li> </ul>	<b>Fatigue</b> <b>TATT</b>
<b>Dysarthria/Dysphagia/Dysphasia</b> Difficulties with speech/swallowing/words	<b>Seizure/Fit</b> <b>Collapse / Vasovagal</b> <b>Loss of consciousness</b>	<b>(Simple) Faint</b>
<b>Bowel Incontinence</b> Male urinary <b>Incontinence</b>	<b>Weakness</b> <ul style="list-style-type: none"> <li>Paresis</li> </ul>	Female urinary <b>Incontinence</b>
	<b>Visual Disturbance</b>	
	<b>Tremor</b>	



# Too much Too young... context is key



KEY	CONTEXT	
Onset	<p>Years ago</p> <p>No changes</p>	<p>Recent onset</p> <p>Changes in presentation</p>
Pre-Presentation	<p>Apparent precipitating cause / factors</p>	<p>No apparent precipitating cause / factors</p>
Presentation Nature of symptoms	<p>Sudden onset</p> <p>No associated symptoms</p>	<p>Gradual onset</p> <p>Associated symptoms</p> <p>Symptoms develop</p>
Duration	<p>Seconds / Minutes / Hours</p>	<p>Hours / Days / Weeks+</p>
Pattern	<p>Acute</p> <p>One off</p> <p>Short lived</p>	<p>Persistent</p> <p>Chronic</p> <p>Intermittent recurrences</p> <p>Constant</p>
Investigations Referrals	<p>Clinical history</p> <p>Clinical exam</p> <p>Bloods</p>	<p>Specialist referral</p> <p>MRI brain/spine</p> <p>CTA/MRA</p> <p>Lumbar puncture</p>
Risk Factors	<p>No family history</p> <p>No associated risk factors</p>	<p>Family history</p>



# Too much Too young... asking the right question

Are you awaiting the results of, or have you been *advised to have*, any medical investigations, tests or scans or have you any *expectation* of seeking *medical advice* or treatment in the near future?

Any *condition affecting* your stomach, oesophagus or bowel, for example crohn's disease, ulcerative colitis?

- Application form questions can be open to interpretation by:-
  - The insurer
  - The consumer
  - The ombudsman
- Terminology potentially impacting on claim experience:
  - Intention or expectation
  - Condition, disease or disorder
  - Problem
  - Suffering or suffered (from)
  - Affecting
  - Medical advice
- There is a growing importance on communication between underwriters and claims
  - Application questions
  - Exclusion wording
  - CI definitions



# Too much Too young ... critical illness conclusion

When comparing insured lives to the general population, for certain conditions, we are seeing:-

- **Materially higher proportions of claims...**
- **Significantly lower age at diagnosis...**
- **Cover levels purchased being higher than average...**
- **Duration from inception to claim being lower than expected...**

**So, what can we learn from this?**



# Too much Too young... critical illness conclusion

- Evidence suggests CI is at high risk of **anti-selection**
- Technology and medicine have evolved since the CI product was launched so insurers need to remain **one step ahead of the consumer**
- We need to ensure application form questions, terminology and automated underwriting rules **evolve** with 'real-world' claims experience

## And finally...

- Underwriters continue to play a key role in safeguarding their office experience (and rates) by preventing avoidable claims through:-
  - Identifying potentially **anti-selective** purchase behaviour
  - Detecting **atypical risks**
  - Obtaining the right **evidence** on atypical risks



**Questions**

**Comments**

